Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy
2006-002330-38Phase 4Terminated
- Sponsor
- King's College London
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in kidney allograft rejection and Chronic Allograft Kidney Disease (CKaD) (2 arms), sponsored by King's College London. Primary endpoint: Rate of deterioration in renal function. Started Oct 2006; status: terminated.
02
Drugs
rituximab
03
Conditions
kidney allograft rejectionChronic Allograft Kidney Disease (CKaD)
Beyond the preview
Go deeper on 2006-002330-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002330-38.